We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Congenital Cytomegalovirus Infection Predicted in High-Risk Pregnant Women

By LabMedica International staff writers
Posted on 08 Dec 2016
Print article
Image: Transmission electron microscopic (TEM) depicts numbers of cytomegalovirus (CMV) virions that were present in a tissue sample (Photo courtesy of Sylvia Whitfield).
Image: Transmission electron microscopic (TEM) depicts numbers of cytomegalovirus (CMV) virions that were present in a tissue sample (Photo courtesy of Sylvia Whitfield).
Congenital cytomegalovirus (CMV) infection can cause serious complications such as hearing difficulties and mental delay in affected infants. A new method for predicting congenital CMV infection during the prenatal period has been discovered. This method is safe for both mothers and fetuses, and could potentially be adopted for general use.

In the USA over 8,000 children a year suffer from the long-term complications of congenital CMV infection and the annual costs of caring for these children are estimated at USD 1-2 billions. To facilitate this, early diagnosis is vital; however, tests to identify the infection in infants, such as molecular tests that detect virus DNA in infants' urine, are not widely carried out, and would incur huge financial costs if they were carried out for all infants.

Scientists affiliated with the Kobe University Graduate School of Medicine (Kobe, Japan) surveyed 300 pregnant women who tested positive for CMV immunoglobulin M (IgM) antibodies and were classified as high-risk for congenital infection. The team carried out clinical interviews, blood tests, ultrasounds, and DNA polymerase chain reaction (PCR) tests for CMV using samples of the subjects' blood, urine and uterine cervical secretion. The maternal clinical and laboratory findings, including serum CMV IgM and IgG, IgG avidity index (AI), direct immunoperoxidase staining of leukocytes with peroxidase-labeled monoclonal antibody (C7-HRP test) testing, and PCR for the detection of CMV-DNA in the maternal serum, urine, and uterine cervical secretion, and prenatal ultrasound findings were evaluated.

The team reported that in 22 of the 300 women, congenital infection was confirmed using PCR for CMV-DNA in newborn urine. Univariate analyses demonstrated that the presence of maternal flu-like symptoms, presence of ultrasound fetal abnormalities, serum titers of CMV IgM, positive results for C7-HRP, CMV IgG AI less than 40%, and positive PCR results in the uterine cervical secretion were statistically associated with the occurrence of congenital CMV infection. Multivariable analysis revealed that the presence of ultrasound fetal abnormalities and positive PCR results in the uterine cervical secretion were independent predictive factors of congenital CMV infection in CMV IgM-positive women.

The authors concluded that both ultrasound and PCR tests for uterine cervical secretion are non-invasive procedures, and using them can offer a safer method to test high-risk pregnant women and predict the occurrence of congenital infection. Accurately identifying the affected infants enables doctors to start antiviral treatment early, and could improve the neurological prognosis of infants infected by CMV. The study was published online on October, 20, 2016, in the journal Clinical Infectious Diseases.

Related Links:
Kobe University Graduate School of Medicine

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.